In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Mounjaro, the brand name for tirzepatide, is a drug that treats type 2 diabetes by lowering blood sugar levels. According to ...

,A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is sold under the brand name Mounjaro and affects feelings of hunger and ...

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a shortage of the brand-name drug has ended ...

Williams began taking compounded tirzepatide for weight loss last year after her Mounjaro savings card expired. She couldn’t afford the $1,060 a month out of pocket for the brand-name drug.

The FDA has agreed to revisit its decision to prevent compounders from selling versions of Eli Lilly's diabetes and weight ...

FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide ... pharmacies can make versions that are copies of the brand-name drugs in shortage. But the agency’s Oct. 2 ...